Rohab Sohail

Dr. Rohab Sohail


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2025 in Journal of Sleep Research
Verified
Journal Article
Closed access
SMSana Murtaza
Sana Murtaza
RSRohab Sohail
Rohab Sohail
BABisma Akram
Bisma Akram
STSameen Tahira
Sameen Tahira
MZMaham Zaman
Maham Zaman
SMSyed Nazeer Mehmood
Syed Nazeer Mehmood

28 May 2025 in medtigo Journal of Medicine
Verified
Journal Article
Open access
RSRohab Sohail
Rohab Sohail
RKRidda Khattak
Ridda Khattak
RMRamsha Mumtaz
Ramsha Mumtaz
AGAnsab Godil
Ansab Godil
SASana Aijaz
Sana Aijaz
AAAdeel Ahmed
Adeel Ahmed
IHCC mortality in U.S. adults over 25 increased from 1999 to 2020. Learn which groups are most at risk and why it matters.

28 March 2023
Verified
Preprint
Open access
PDF file
TPTirath Patel
Tirath Patel
RSRohab Sohail
Rohab Sohail
Adaptive deep brain stimulation (aDBS) is a promising therapy for Parkinson's disease (PD) that has the potential to improve treatment outcomes and reduce side effects compared to traditional, continuous DBS. In aDBS, the stimulation parameters are adjusted in real-time based on feedback from the patient's brain signals or symptoms. This allows for more precise and personalized stimulation, tailored to the patient's needs and fluctuating symptoms. Several studies have demonstrated the feasibility and effectiveness of aDBS in PD patients, with improvements in motor symptoms, quality of life, and reduction in medication usage. Furthermore, aDBS may have the potential to reduce the incidence of DBS-related side effects, such as speech and gait disturbances, as well as decrease battery usage and prolong device longevity. Despite the promising results, aDBS is still in the early stages of development and requires further research to fully understand its mechanisms and optimize its parameters. Challenges remain in identifying the optimal biomarkers for aDBS, designing closed-loop systems that can effectively integrate feedback signals and stimulation parameters, and assessing long-term efficacy and safety. In conclusion, aDBS is a promising approach that has the potential to revolutionize DBS therapy for PD. Further research is needed to refine the technology, identify the optimal biomarkers, and determine the most effective stimulation strategies for individual patients.

9 May 2024 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
HMHafsa Mansoor
Hafsa Mansoor
RSRohab Sohail
Rohab Sohail

28 August 2024 in International Journal of Scientific Reports
Verified
Journal Article
Open access
PDF file
AIAimen
Aimen
MGMuhammad Hmaza Gul
Muhammad Hmaza Gul
RSRohab Sohail
Rohab Sohail
RPRitesh Pahwan
Ritesh Pahwan
ASAisha R. Siddiqui
Aisha R. Siddiqui
AAAftab Ahmed
Aftab Ahmed
Alzheimer’s disease is a comprehensive clinical syndrome featuring cognitive, emotional, and volitional function deterioration. Treatment strategies for Alzheimer's disease involve a mix of pharmacological and non-pharmacological approaches. Current treatments focus on palliative care with limited impact on the disease course. Venom-derived substances, known for their neuroactive properties, have emerged as a novel approach to Alzheimer's treatment. Our team conducted a thorough search for electronic literature related to therapeutic venom-derived substances efficacy in Alzheimer’s disease in different databases, including Medline, PubMed, Google Scholar, and Psych INFO, up to May 2024. In this article, the therapeutic effects of various venom-derived substances effects in Alzheimer’s disease are discussed. Various substances grant anti-inflammatory and anti-oxidant effects. The clinical application of venom-derived therapy is still a long way ahead, still, researchers believe that the ongoing work will eventually allow its compounds to be considered definitive candidates in various therapies in upcoming years.